Close Menu

Decision Biomarkers

Movers & Shakers: Jul 29, 2011

Premium

Glenn Barney, Dario Alessi, Philip Cohen, Stephane Bancel, Noubar Afeyan

Avantra was founded last year by Courtagen Capital Group to commercialize the assets of Decision Biomarkers, a protein biomarker technology firm that shuttered its business and filed for Chapter 7 bankruptcy in December 2009.

The company is being launched by Courtagen Capital Group using assets from defunct biotech firm Decision Biomarkers, which Courtagen purchased in bankruptcy court last December.

The demise of Perlegen Sciences and Decision Biomarkers adds two more names to a growing list of array-related firms and businesses that have gone belly up or have been shuttered in the past few years.

The company, formed in 2003, had raised at least $15.1 million in financing in its history, but in its bankruptcy filing said that its liabilities were at least 20 times that of its assets.

The Waltham, Mass.-based biomarker-detection company ceased operations and filed for Chapter 7 bankruptcy last month.

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

Time magazine looks into how liquid biopsies are changing cancer care.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.